SCHEMBL747314

SCHEMBL747314

CCCCCCCCC=CCCCCCCCC(=O)OCCN1CCN(CCO)C1CCCCCCCC=CCCCCCCCC

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.51
EPHX2 P34913 1/20 0.47
DGKA P23743 2/20 0.46
PRKCE Q02156 1/20 0.45
PRKCQ Q04759 1/20 0.45
PRKCD Q05655 1/20 0.45
PRKCA P17252 1/20 0.45
CNR2 P34972 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
CNR1 P21554 1/20 0.44
TRPV1 Q8NER1 1/20 0.42
ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180550 1.00 MGLL (0.51) MGLLEPHX2DGKAPRKCEPRKCQ
SCHEMBL28968652 1.00 MGLL (0.51) MGLLEPHX2DGKAPRKCEPRKCQ
SCHEMBL441411 1.00 MGLL (0.51) MGLLEPHX2DGKAPRKCEPRKCQ
Water SCHEMBL6549699 0.99 MGLL (0.50) MGLLEPHX2DGKAPRKCEPRKCQ
Hydrochloric Acid SCHEMBL421821 0.99 MGLL (0.50) MGLLEPHX2DGKAPRKCEPRKCQ
Hydrochloric Acid SCHEMBL1047267 0.99 MGLL (0.50) MGLLEPHX2DGKAPRKCEPRKCQ
Hydrochloric Acid SCHEMBL29396916 0.99 MGLL (0.50) MGLLEPHX2DGKAPRKCEPRKCQ
Hydrochloric Acid SCHEMBL28736736 0.98 MGLL (0.49) MGLLEPHX2DGKAPRKCEPRKCQ
SCHEMBL1044584 0.93 DGKA (0.50) MGLLEPHX2DGKAPRKCEPRKCQ
Hydrochloric Acid SCHEMBL18209372 0.92 DGKA (0.49) MGLLEPHX2DGKAPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0730404-B1 AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES VALENTIS INC (US) 2004-02-04 EP claimed
US-12616678-B2 Methods to of aldehyde dehydrogenases for treatment of cancer THE PENN STATE RESEARCH FOUNDATION (PA) 2026-05-05 US disclosed
US-12551434-B2 Zwitterionic polymer particle compositions and related methods WAYNE STATE UNIVERSITY (US) 2026-02-17 US disclosed
US-20250387367-A1 METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER PENN STATE RES FOUND (US) 2025-12-25 US disclosed
US-12036265-B2 Compositions and methods relating to bone repair and regeneration WAYNE STATE UNIVERSITY (US) 2024-07-16 US disclosed
WO-2023235392-A1 ELECTROPHORESIS-MEDIATED CHARACTERIZATION OF DNA CONTENT OF ADENO-ASSOCIATED VIRUS CAPSIDS PERKINELMER HEALTH SCIENCES, INC. (US) 2023-12-07 WO disclosed
US-20230392188-A1 ELECTROPHORESIS-MEDIATED CHARACTERIZATION OF DNA CONTENT OF ADENO-ASSOCIATED VIRUS CAPSIDS REVVITY HEALTH SCIENCES, INC. 2023-12-07 US disclosed
US-20230301965-A1 METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER THE PENN STATE RESEARCH FOUNDATION 2023-09-28 US disclosed
US-20230225969-A1 ZWITTERIONIC POLYMER PARTICLE COMPOSITIONS AND RELATED METHODS WAYNE STATE UNIVERSITY 2023-07-20 US disclosed
CN-116348126-A Antiviral compositions and methods 韦恩州立大学 2023-06-27 CN disclosed
EP-2430001-A1 METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS Juvaris Biotherapeutics, Inc. (US) 2012-03-21 EP disclosed
US-8044215-B2 Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds JUVARIS BIOTHERAPEUTICS, INC. (US) 2011-10-25 US disclosed
US-20110229972-A1 COMPOSITIONS AND METHODS FOR MATERIAL TRANSFER INTO CELLS THE PENN STATE RESEARCH FOUNDATION (US) 2011-09-22 US disclosed
WO-2011116383-A2 COMPOSITIONS AND METHODS FOR MATERIAL TRANSFER INTO CELLS THE PENN STATE RESEARCH FOUNDATION (US) 2011-09-22 WO disclosed
WO-2010126978-A1 METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS JUVARIS BIOTHERAPEUTICS, INC. (US) 2010-11-04 WO disclosed
US-20100280258-A1 METHODS FOR THE PREPARATION OF AMPHILLIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS JUVARIS BIOTHERAPEUTICS, INC. (US) 2010-11-04 US disclosed
EP-0730404-B1 AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES VALENTIS INC (US) 2004-02-04 EP disclosed
EP-0730404-A4 AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES MEGABIOS CORP (US) 1997-02-19 EP disclosed
EP-0730404-A1 AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES MEGABIOS CORPORATION (US) 1996-09-11 EP disclosed
WO-1995014380-A1 AMPHIPHILIC IMIDAZOLINIUM DERIVATIVES MEGABIOS CORPORATION (US) 1995-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230225969-A1 ZWITTERIONIC POLYMER PARTICLE COMPOSITIONS AND RELATED METHODS IAPP, IGFBP6, SI MGLL 886/4885EPHX2 3460/4885DGKA 1504/4885
US-20100280258-A1 METHODS FOR THE PREPARATION OF AMPHILLIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS NDC1, NUP205, NUP188 MGLL 533/4885EPHX2 4612/4885DGKA 503/4885
US-20250387367-A1 METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER ALDH3A1, ALDH2, ADH1C MGLL 316/4885EPHX2 263/4885DGKA 1266/4885
US-12616678-B2 Methods to of aldehyde dehydrogenases for treatment of cancer ALDH1A1, ALDH3A1, ADH1C MGLL 175/4885EPHX2 133/4885DGKA 1423/4885
US-12551434-B2 Zwitterionic polymer particle compositions and related methods IAPP, GIPR, INSR MGLL 81/4885EPHX2 3504/4885DGKA 1498/4885
US-20230301965-A1 METHODS AND COMPOSITIONS RELATING TO INHIBITION OF ALDEHYDE DEHYDROGENASES FOR TREATMENT OF CANCER DPYD, ALDH2, DLD MGLL 1204/4885EPHX2 517/4885DGKA 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.